100 Cell cycle and tumor resistance profiling in breast cancer by a 17-plex immunofluorescence assay on the Orion platform
Jacob Levy(Navidea Biopharmaceuticals (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Lisa Kattenhorn(American Institutes for Research), Richard Van Krieken(Lineage Cell Therapeutics (United States)), Sophia Kekchidou(Lineage Cell Therapeutics (United States)), Xun Li(Navidea Biopharmaceuticals (United States)), Ying Huang, David T. Yang(University of Wisconsin–Madison), LaSalette Charette(Novartis (United States))
Cited by 0
Related Papers
Antibody validation
|BioTechniques|2010|601
Linear Motif Atlas for Phosphorylation-Dependent Signaling
|Science Signaling|2008|465
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
|Clinical Cancer Research|2022|226